#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
In this article, Bertha Madras discusses the differences between tetrahydrocannabinol (THC) and 2-arachidonoylglycerol (2-AG) in their binding to cannabinoid receptors, specifically the CB1 domain. This distinction leads to varying effects on the endocannabinoid system, which may have implications for clinicians when considering the therapeutic use of cannabis and its potential side effects for patients. The practical takeaway is that understanding these differences can aid in the informed prescribing and management of cannabis-based treatments.
🔬 In the article discussing Bertha Madras’ work on X, it’s highlighted that tetrahydrocannabinol (THC) and 2-arachidonoylglycerol (2-AG) interact differently with cannabinoid receptors, particularly CB1. This distinction is significant as it may influence the clinical effects of cannabis in patients. However, it’s important to acknowledge that the complexity of the endocannabinoid system and individual variability can confound these findings. In practice, healthcare providers should remain vigilant about potential cannabis-related side effects and adjust treatment plans accordingly, considering each patient’s unique response to cannabis and other medications.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
